Equity · Healthcare
CYTK
NASDAQCytokinetics (CYTK)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for CYTK to draw a line in its place.
- Market cap
- 11.3B USD
- Revenue, year to Dec 2025
- 88.0M USD
- EPS, diluted, year to Dec 2025
- −6.54 USD
- 52-week range
- 33.20 USD – 87.31 USD
- Avg volume
- 477.5K
as of Jul 24, 2026
Have Cytokinetics (CYTK) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Cytokinetics insiders reported 16 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Apr 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 3 Nov 2026
Buys 0Sells 16Net sold $11.93MOther filings 19
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | 220K USD |
| 02 Nov 2026 | Blum Robert IPresident & CEO | Sell | 7,500 | 471K USD |
| 20 Oct 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | 224K USD |
| 12 Oct 2026 | Blum Robert IPresident & CEO | Sell | 7,500 | 472K USD |
| 06 Oct 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | 215K USD |
| 28 Sep 2026 | Blum Robert IPresident & CEO | Sell | 7,500 | 491K USD |
| 22 Sep 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | 239K USD |
| 15 Sep 2026 | Blum Robert IPresident & CEO | Sell | 97,926 | 6.8M USD |
| 15 Sep 2026 | Landry Robert EDirector | Sell | 1,000 | 72K USD |
| 14 Sep 2026 | Blum Robert IPresident & CEO | Sell | 7,500 | 551K USD |
| 11 Sep 2026 | Landry Robert EDirector | Sell | 1,000 | 75K USD |
| 08 Sep 2026 | Malik Fady IbrahamEVP Research & Development | Sell | 3,500 | 264K USD |
| Sold | 16 open-market sales | 173,426 | $11.93M |
Showing the 12 most recent of 16 open-market trades in this window. The figures above count all of them.
19 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Nov 2026 | Malik Fady IbrahamEVP Research & Development | Option exercise | 3,500 | 27K USD |
| 02 Nov 2026 | Blum Robert IPresident & CEO | Option exercise | 7,500 | 80K USD |
| 20 Oct 2026 | Malik Fady IbrahamEVP Research & Development | Option exercise | 3,500 | 27K USD |
| 16 Oct 2026 | HENDERSON JOHN TDirector | Award | 352 | 22K USD |
| 16 Oct 2026 | WIERENGA WENDELLDirector | Award | 97 | 6K USD |
| 16 Oct 2026 | Daly James MDirector | Award | 195 | 12K USD |
| 16 Oct 2026 | Harrington Robert ArthurDirector | Award | 195 | 12K USD |
| 16 Oct 2026 | Kaye Edward M. MDDirector | Award | 195 | 12K USD |
| 16 Oct 2026 | Wysenski NancyDirector | Award | 97 | 6K USD |
| 12 Oct 2026 | Blum Robert IPresident & CEO | Option exercise | 7,500 | 80K USD |
| 06 Oct 2026 | Malik Fady IbrahamEVP Research & Development | Option exercise | 3,500 | 27K USD |
| 28 Sep 2026 | Blum Robert IPresident & CEO | Option exercise | 7,500 | 80K USD |
Showing the 12 most recent of 19 compensation filings in this window. The figures above count all of them.
Which funds hold Cytokinetics (CYTK)?
1 of the 45 institutional funds we track reported a Cytokinetics position for the quarter ended 30 Sep 2026 — a combined 54.0M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 818,832 | 54.0M USD | +10.1% |
Have members of Congress traded Cytokinetics (CYTK)?
The most recent congressional trade disclosed in Cytokinetics is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 29 Sep 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 13 days |
| 30 Jun 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 2 days |
| 09 Oct 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 40 days |
| 17 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Sale | 1K USD–15K USD | 57 days |
| 11 Jun 2025 | Lisa C. McClainhouse · Republican–MI | Purchase | 1K USD–15K USD | 63 days |
What has been filed or recorded for Cytokinetics (CYTK)?
The filings we hold for Cytokinetics, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 236 shares | 15K USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 386 shares | 24K USD notional · <0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 105 shares | 7K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 2,845 shares | 187K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.37 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.8B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −321.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.50 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.67 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −6.54 USD | |
| 31 Dec 2025 | Financials | Revenue | 88.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −785.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −6.54 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −2.55 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −1.12 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.36 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −5.26 USD |
Cytokinetics (CYTK): frequently asked questions
What is Cytokinetics’ market cap?
Cytokinetics is worth 11.3B USD by market value as of 24 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Cytokinetics’ revenue?
Cytokinetics reported revenue of 88.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Cytokinetics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Cytokinetics insiders reported 16 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 15 Apr 2026, show no open-market purchase. A further 19 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Cytokinetics?
1 of the 45 funds we track reported a Cytokinetics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded Cytokinetics?
Yes. 5 trades in Cytokinetics appear in the congressional disclosures we hold; the latest is a purchase by Gilbert Ray Cisneros, Jr. (House, CA) dated 29 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Cytokinetics last report earnings?
Cytokinetics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.37 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings